---
run_id: halo-evidence-vs-diagnosis-validation-v8-vanilla-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: vanilla
run_number: 5
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 501
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `vanilla`, run 5 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 501, on the frozen condition packet.

## Output

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current "upbeat" story is a lagging indicator built on financial engineering, not product-market fit. 72% of your expansion revenue is artificial—bought via short-term discounts to pull forward renewals—which creates a "revenue cliff" in six months. More critically, the product is failing its primary user: the front-line reviewer. A 31% week-one retention rate for the actual workers is a catastrophic failure in a B2B workflow tool, regardless of what "champions" (who are merely prepping for meetings) or Account Managers say.

If you scale now (Option 1), you are scaling a leaky bucket and committing the budget to a revenue-led plan based on a mirage. If you narrow to regulated insurance (Option 3), you are pivoting the entire company to solve a specific "explainability" problem before you've even proven that the general triage logic works for the broader market. The evidence pass is the only move that protects the company from a massive churn event next year by forcing the organization to distinguish between "buying a feature" and "adopting a workflow."

**The strongest reason against this:**
It kills the current momentum and risks the "upbeat" narrative heading into the board meeting. By pausing discounts and instrumenting behavior, you are effectively telling the board and Sales leadership that the recent revenue spike is an illusion. This will be perceived as "product pessimism" and may create friction with Sales leadership who have already mentally banked the "market wedge" victory.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" only if the evidence pass reveals that the 31% front-line retention rate is an industry-standard baseline for this specific compliance task, AND that the "champion" usage is driving a measurable reduction in total case-handling time across the account (meaning the champions are successfully optimizing the system for the front-line, even if the front-line isn't "logging in" frequently). If the value is being captured systemically rather than individually, the low individual retention is a noise metric, not a signal of failure.
